Efficacy and Safety of Ethanol Lock Therapy for the Prevention of Central Line-associated Bloodstream Infections



Status:Terminated
Conditions:Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - 80
Updated:11/1/2017
Start Date:August 2016
End Date:September 2019

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
Patients on long-term parenteral nutrition (PN) are at high risk for central line-associated
bloodstream infections (CLABSI). This study evaluates the efficacy and safety of ethanol lock
therapy for CLABSI prophylaxis in adult patients on PN.


Inclusion Criteria:

- Adult patients (ages 18-80) on PN with silicone-based central venous catheters

Exclusion Criteria:

- Weight ≤ 50 kg

- Allergy/hypersensitivity/intolerance to ethanol or heparin

- Pregnancy or breastfeeding

- Patient taking metronidazole, disulfiram, or isoniazid

- History of alcohol abuse

- History of heparin-induced thrombocytopenia (HIT) or have an active hypocoagulable
state
We found this trial at
1
site
Stanford University
Palo Alto, California 94304
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials